Employer-Paid

Drugmakers cannot replace upfront discounts with their own rebate models without federal approval, although the ruling leaves HHS free to authorize a future system.

The 7.5% increase since last year reflects rising prices for care, continued utilization growth and growing costs tied to chronic conditions, according to the latest Retiree Health Care Cost Estimate from Fidelity Investments.

The industry group says its reform effort remains on track despite questions about participation, oversight and continuity-of-care protections.

Here are three questions to determine whether considering an unconventional design makes sense.

Budget analysts increased the federal group health tax subsidy value estimate 25% in just three years.

The company hopes early action will keep small employer claims from becoming stop-loss claims.